摘要
目的 探讨依达拉奉右莰醇联合胞磷胆碱钠治疗急性进展性脑梗死患者的临床疗效。方法 选取成都双楠医院神经内科2021年1月至2024年8月收治的急性进展性脑梗死患者103例,通过计算机生成随机序列分为对照组(胞磷胆碱钠单药,51例)与观察组(胞磷胆碱钠联合依达拉奉右莰醇,52例)。评估两组治疗方案的临床疗效、氧化应激反应指标、炎症水平及药物安全性方面的差异。结果 观察组治疗总有效率[90.38%(47/52)]高于对照组[74.51%(38/51)](χ^(2)=4.499,P<0.05)。治疗后,两组患者活性氧簇(reactive oxygen species,ROS)、丙二醛(malondialdehyde,MDA)水平均较治疗前降低,超氧化物歧化酶(superoxide dismutase,SOD)水平较治疗前升高,且观察组ROS、MDA[分别为(451.67±46.67)μmol·L^(-1)、(4.16±0.62)nmol·L^(-1)]均低于对照组[分别为(546.19±41.78)μmol·L^(-1)、(5.34±0.54)nmol·L^(-1)],观察组SOD水平[(101.64±8.77)U·mL^(-1)]高于对照组[(86.54±8.56)U·mL^(-1)](t=10.834、10.292、8.841,均P<0.05)。治疗后,两组患者的白细胞介素6(interleukin-6,IL-6)、肿瘤坏死因子α(tumor necrosis factor-alpha,TNF-α)、超敏C反应蛋白(high-sensitivity C-reactive protein,hs-CRP)水平均低于治疗前,且观察组IL-6、TNF-α、hs-CRP[分别为(16.78±3.78)ng·L^(-1)、(18.54±2.43)ng·L^(-1)、(5.34±1.37)mg·L^(-1)]均低于对照组[分别为(24.67±4.89)ng·L^(-1)、(23.77±2.65)ng·L^(-1)、(7.25±1.23)mg·L^(-1)](t=9.172、10.443、7.440,均P<0.05)。对照组不良反应发生率为15.69%(8/51),观察组为13.46%(7/52),组间差异无统计学意义(χ^(2)=0.102,P>0.05)。结论 依达拉奉右莰醇联合胞磷胆碱钠治疗急性进展性脑梗死的临床疗效较好,能改善氧化应激反应指标,减轻炎症反应,且安全性较高。
Objective To investigate the clinical efficacy of edaravone and dexborneol combined with citicoline sodium in the treatment of the patients with acute progressive cerebral infarction.Methods A total of 103 patients who were diagnosed with acute progressive cerebral infarction and treated in the Department of Neurology of Chengdu Shuangnan Hospital between January 2021 and August 2024 were enrolled in the study and divided into two groups by computer-generated randomization.The control group with 51 cases was treated with citicoline sodium monotherapy,and the observation group with 52 cases was given combination therapy of citicoline sodium and edaravone dexborneol.The differences in clinical efficacy,oxidative stress response,inflammation level,and drug safety between the two groups were evaluated.Results The effective rate of the observation group was 90.38%(47/52),higher than 74.51%(38/51)of the control group(χ²=4.499,P<0.05).The reactive oxygen species(ROS)and malondialdehyde(MDA)levels of the two groups were lower after the treatment than before the treatment,while the superoxide dismutase(SOD)levels were higher after the treatment than before the treatment.The ROS and MDA levels of the observation group were respectively(451.67±46.67)μmol·L^(-1) and(4.16±0.62)nmol·L^(-1),lower than(546.19±41.78)μmol·L^(-1) and(5.34±0.54)nmol·L^(-1);the SOD level of the observation group was(101.64±8.77)U·mL^(-1),higher than(86.54±8.56)U·mL^(-1) of the control group(t=10.834,10.292,8.841,all P<0.05).The interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),and high-sensitivity C-reactive protein(hs-CRP)levels of the two groups were lower after the treatment than before the treatment.The IL-6,TNF-α,and hs-CRP levels of the observation group were respectively(16.78±3.78)ng·L^(-1),(18.54±2.43)ng·L^(-1),and(5.34±1.37)mg·L^(-1),lower than(24.67±4.89)ng·L^(-1),(23.77±2.65)ng·L^(-1),and(7.25±1.23)mg·L^(-1) of the control group(t=9.172,10.443,7.440,all P<0.05).The incidence of adverse reactions was 15.69%(8/51)in the control group and 13.46%(7/52)in the observation group,and there was no significant difference between the two groups(χ²=0.102,P>0.05).Conclusion The combination of edaravone and dexborneol with citicoline sodium demonstrates favorable clinical efficacy in treating acute progressive cerebral infarction.It improves oxidative stress markers,reduces inflammatory responses,and exhibits a favorable safety profile.
作者
李宛真
杨嵩
伍莉
郭富强
Li Wanzhen;Yang Song;Wu Li;Guo Fuqiang(Department of Neurology,Chengdu Shuangnan Hospital,Chengdu 610047,China)
出处
《中国药物应用与监测》
2025年第4期581-584,共4页
Chinese Journal of Drug Application and Monitoring
基金
四川省中央引导地方科技发展专项项目(2023ZYD0048)。
关键词
依达拉奉右莰醇
胞磷胆碱钠
急性进展性脑梗死
炎症因子
氧化应激
Edaravone and dexborneol
Citicoline sodium
Acute progressive cerebral infarction
Inflammatory factor
Oxidative stress
作者简介
通信作者:郭富强,Email:guofuqiang2005@126.com。
